SCHEMBL21753503

SCHEMBL21753503

CCOC(=O)C(=NNC(=O)OC(C)(C)C)C(=O)Cc1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
CYP1A2 P05177 2/20 0.43
KDM4E B2RXH2 3/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KCNQ4 P56696 2/20 0.40
KCNQ5 Q9NR82 2/20 0.40
GAA P10253 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
RAB9A P51151 5/20 0.39
NPC1 O15118 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
CES2 O00748 1/20 0.37
ACHE P22303 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21185628 1.00 MAPT (0.43) MAPTCYP1A2KDM4EMEN1KMT2A
SCHEMBL22704140 0.91 NPC1 (0.40) MAPTCYP1A2KDM4EMEN1KMT2A
SCHEMBL25037566 0.89 MAPT (0.43) MAPTMEN1KMT2ANPSR1GAA
SCHEMBL29155091 0.86 CTSS (0.43) MAPTKDM4EMEN1KMT2AKCNQ4
SCHEMBL16559311 0.79 MAPT (0.39) MAPTCYP1A2KDM4EMEN1KMT2A
SCHEMBL25037571 0.79 MAPT (0.39) MAPTCYP1A2KDM4EMEN1KMT2A
SCHEMBL21769297 0.77 RAB9A (0.43) MAPTCYP1A2KDM4EMEN1KMT2A
SCHEMBL22684774 0.76 MAPT (0.49) MAPTCYP1A2KDM4EMEN1KMT2A
SCHEMBL22684775 0.76 MAPT (0.49) MAPTCYP1A2KDM4EMEN1KMT2A
SCHEMBL21185442 0.76 MAPT (0.49) MAPTCYP1A2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3842425-B1 NOVEL QUINOLINE DERIVATIVE INHIBITOR TRANSTHERA SCIENCES NANJING INC (CN) 2024-05-22 EP disclosed
CN-110857293-B Novel quinoline derivative inhibitor 药捷安康(南京)科技股份有限公司 2023-01-10 CN disclosed
CN-110041316-B TAM family kinase/CSF 1R kinase inhibitors and uses thereof 药捷安康(南京)科技股份有限公司 2022-04-19 CN disclosed
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-03-10 US disclosed
EP-3842425-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR Nanjing Transthera Biosciences Co., Ltd. (CN) 2021-06-30 EP disclosed
US-20210177828-A1 TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF TRANSTHERA SCIENCES (NANJING), INC. (CN) 2021-06-17 US disclosed
EP-3741752-A1 TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF Nanjing Transthera Biosciences Co., Ltd. (CN) 2020-11-25 EP disclosed
CN-110857293-A Novel quinoline derivative inhibitor 南京药捷安康生物科技有限公司 2020-03-03 CN disclosed
WO-2020038460-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR 南京药捷安康生物科技有限公司 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR CSF1R, CSF3R, FLT3 MAPT 2342/4885CYP1A2 2757/4885KDM4E 2855/4885
US-20210177828-A1 TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF CSF1R, CSF3R, FLT3 MAPT 3340/4885CYP1A2 4134/4885KDM4E 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.